蒙克18-1是痴呆症的多方面的治疗点
Khuraijam Surjalal Singh1, Prachi Rani1, Anuja Arora1
1Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, Delhi 110007, India.
Ageing research reviews
|September 19, 2025
概括
Munc18-1 (STXBP1) 蛋白质是痴呆症的中心调节者,影响粉样蛋白,和α-synuclein通路. 稳定Munc18-1为治疗痴呆症提供了一个新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 病理学 病理学 病理学
背景情况:
- 痴呆症涉及复杂的多因素病理,如粉样蛋白-β (Aβ) 积累,陶病和神经炎症.
- 由于该病的复杂性,对痴呆症的单一向疗法取得的成功有限.
- 识别集成多种病理途径的分子枢纽对于有效的痴呆症治疗至关重要.
研究的目的:
- 研究Munc18-1 (STXBP1) 作为连接不同痴呆病理生理学的中央调节器.
- 探索Munc18-1稳定作为痴呆症新型治疗策略的潜力.
主要方法:
- 对Munc18-1在突触功能和痴呆病理学中的作用的现有文献的审查.
- 对Munc18-1与粉样前体蛋白 (APP),Tau和α-synuclein的相互作用进行分析.
- 检查Munc18-1对突触完整性,BDNF信号传递和神经炎症的影响.
主要成果:
- Munc18-1 调节神经递质释放,APP 处理,Tau 酸化和α-synuclein.
- Munc18-1功能障碍与突触完整性受损,BDNF信号传输受损和神经炎症有关.
- 降低Munc18-1水平或突变与痴呆症模型中的认知衰退相关.
结论:
- Munc18-1作为一个主调节器,整合了多种痴呆相关的病理生理学.
- 针对Munc18-1稳定性的治疗策略可能为痴呆症治疗提供一种新的方法.
- 恢复Munc18-1的多方面的功能为痴呆症治疗提供了一个有前途的途径.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
28.0K
相关概念视频
01:22Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Dementia
526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
526
01:24Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K